The UK Passes Medicines and Medical Devices Act

Published on April 15,2021

The UK Passes Medicines and Medical Devices Act

Industry Update

The United Kingdom (UK) has passed an important Act to make provision about a Commissioner for Patient Safety in relation to human medicines and medical devices. The Medicines and Medical Devices Act of 2021, known as MMDA 2021, received royal assent and was passed into law on February 11, 2021.

The Act is designed such as to ensure that regulatory change can be made as and when deemed necessary. It allows for the UK Government to amend legislation on human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The Government say this will ensure that UK legislation is more responsive to new advances in medical technology. This framework is designed so that updates to current legislation must take into account the safety, availability of human medicines and medical devices.

The language in the document focuses on patient safety. This act establishes a framework by which the UK will regulate its pharmaceutical and biotech industries. MMDA 2021 provides punishment for those who violate its terms with civil and criminal sanctions. Other key provisions of the act include:

Powers granted to the Secretary of State for Health and Social Care, to amend current regulations    governing human and veterinary medicines, clinical trials, and medical devices

Focus on patient safety

Balance to promote innovation while maintaining public safety

Establishment of a new Commissioner for Public Safety

This unique legislation also allows for broader prescription of low-risk medicines and includes provisions that allow hospitals to develop and provide personalized medicines.

How Can Symbiance AI Help?

Awareness and smarter implementation of clinical activity requirements are key to ensure that regulations and applicable standards are followed. Meeting these requirements will ensure efficient clinical activities, reduce delays and minimize costs and business risks.

Symbiance AI is a new-age organization designed to empower clinical research management (R&D) with advancing technologies such as AI and automation to meet clinical research needs. We help global bio-pharmaceuticals at all stages of the clinical trial, including data preparation and standardization, visualization, analysis, and reporting. With our unique AI enabled solutions we help you get quality, compliant products to market faster.

Was this post helpful? Learn more about our products and solutions by contacting Symbiance AI today.



Chandra Shekar Gambiraopet